Stock ZNTL ZENTALIS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Zentalis Pharmaceuticals, Inc.

Equities

ZNTL

US98943L1070

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-17 EDT 		5-day change 1st Jan Change
12.07 USD +0.92% Intraday chart for Zentalis Pharmaceuticals, Inc. -3.59% -20.33%
05-08 Stifel Adjusts Price Target on Zentalis Pharmaceuticals to $32 From $36, Maintains Buy Rating MT
05-07 Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation Summit
AQ
Stifel Adjusts Price Target on Zentalis Pharmaceuticals to $32 From $36, Maintains Buy Rating
MT
Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress
AQ
Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Zentalis Pharmaceuticals, Inc. Announces Executive Changes
CI
Zentalis Pharmaceuticals, Inc. Announces CFO Changes
CI
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS Inhibitors at AACR Annual Meeting 2024
AQ
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024
AQ
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating That Wee1 Inhibitor Azenosertib Exerts Synergistic Anti-Tumor Activity with Kras(G12c) Inhibitors At Aacr Annual Meeting 2024
CI
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Zentalis Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
AQ
Wedbush Raises Zentalis Pharmaceuticals' PT to $15 From $12, Tweaks Financing Assumptions, Says Still on Track to Share Multiple Azenosertib Datasets in 2024, 2025; Keeps Neutral Rating
MT
Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates
AQ
Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences Conference
AQ
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Zentalis Pharmaceuticals Names Chief Medical Officer, Chief Business Officer
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ZNTL Stock
  4. News Zentalis Pharmaceuticals, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW